國家衛生研究院 NHRI:Item 3990099045/2928
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 857857      Online Users : 649
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2928


    Title: Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation
    Authors: Chen, PM;Chiou, TJ;Fan, FS;Liu, JM;Hsieh, RK;Yen, CC;Wang, WS;Liu, JH
    Contributors: National Institute of Cancer Research
    Abstract: Background. Bone marrow transplantation (BMT) is effective treatment for many hematologic disease, but performed in a population with a high endemic hepatitis B virus carrier rate, the incidence of liver function impairment and fulminant hepatitis (FH) is expected to be raised. Methods. Forty three hepatitis B virus carriers received high-dose chemotherapy and BMT, 32 patients received an allogeneic graft, and 11 patients autologous marrow. Acute graft-versus-host disease prophylaxis consisted of methotrexate on day 1, 3, 6, and 11 and cyclosporine for B months. Results. After a median follow-up period of 68 months (range: 1-11.5 years), 26 (81.3%) allogeneic BMT patients developed impaired liver function (LF), 5 progressed to FH on day 93, 169, 170, 180, and 468, respectively, and died after an average of 13.8 days (range: 1-45 days). Whereas only 4 (36.4%) autologous BMT patients developed impaired LF, and none FH, Impaired LF (P=0.026, chi-square), and FH (odds ratio=12.86, P=0.009 for coefficient) were significantly related to an allogeneic marrow graft, and the timing of liver function impairment coincided with cyclosporine withdrawal. Hepatitis B surface antigen (HbsAg) disappeared from the serum in 4/14(28.6%) patients receiving a marrow graft from an HbsAg+ donor, HbsAg was not detected in the serum after BMT in 2/11 (18.2%) autologous BMT patients. Conclusions. Hepatitis B virus carriers receiving a marrow graft from an HbsAg+ donor have a significantly increased risk of FH.
    Keywords: Immunology;Surgery;Transplantation
    Date: 1999-06-15
    Relation: Transplantation. 1999 Jun;67(11):1425-1433.
    Link to: http://dx.doi.org/10.1097/00007890-199906150-00006
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0041-1337&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000080949500006
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0033564450
    Appears in Collections:[Ming Jacqueline Liu(1996-2007)] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI000080949500006.pdf133KbAdobe PDF288View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback